Optimizing Treatment Performance
Canary Health Technologies’ platforms will be part of a point of care breath-based precision medicine drive to help doctors and clinicians track and evaluate the performance of therapy to optimize treatment applications.
This will also enable further identification of sub-populations who respond best to treatment, shaping clinical trial programs and accelerating the development of effective and marketable drugs.
The non-invasive nature, ease of administration, and instant feedback will support its use in repeated testing to track the response to therapy.
Measure
Recurrence rates vary widely between cancer types, and within cancer types according to stage, histology, genetic factors, patient-related factors, and treatments.
Airostotle Track platform enables real-time diagnostic detection and disease monitoring.
Define
Some breath based tumour markers help doctors decide whether to add chemotherapy or immuno-therapy after surgery and/or radiation therapy.
AiroStotle’s Detect platform identifies treatment responders versus non responders.
Guide & Monitor
Other breath based tumor markers help doctors choose which drug(s) or drug combination will work best. Doctors may use changes in breath based tumor markers to figure out how well treatment is working.
266,120 women in the US will be diagnosed with invasive breast cancer in 2018
7 in 10 Early Stage Breast Cancer Patients Will Receive No Benefit from Chemotherapy
/ Sparano et al. N Engl J Med. 2015 / Sparano et al. N Engl J Med. 2018 / Sparano et al. ASCO 2018 / Paik et al. J Clin Oncol. 2006
Canary Health Technologies Track and Detect platforms can match patients with effective treatments earlier than any other technology
more effective treatment results at earlier stages results in significantly better health outcomes for patients
